UCB saw the highest growth of 1.99% in patent filings and 1.41% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.47% and grants by 0.51%. GlobalData’s DataBook provides a comprehensive analysis of UCB‘s patent filings and grants. Buy the databook here.
UCB has been focused on protecting inventions in Australia(AU) with 12 publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings and grants with nearly 16% filings and 12% grants. The World Intellectual Property Organization(WIPO), Australia(AU), United States(US), and Israel(IL) patent Office are among the top ten patent offices where UCB is filings its patents. Among the top granted patent authorities, UCB has 19% of its grants in Israel(IL), 16% in United States(US) and 12% in Australia(AU).
Roche could be the strongest competitor for UCB
In terms of grant share, UCB stands in tenth position among its competitors. UCB and Roche secured the top positions according to recent patent publication data.
Patents related to rare diseases and climate change lead UCB's portfolio
UCB has the highest number of patents in rare diseases followed by, climate change and industrial automation. For rare diseases, nearly 67% of patents were filed and 35% of patents were granted in Q2 2024.
Autoimmune disorders related patents lead UCB portfolio followed by myasthenia gravis, and fibrosis
UCB has highest number of patents in autoimmune disorders followed by myasthenia gravis, fibrosis, lennox-gastaut syndrome, and image management. For autoimmune disorders, nearly 7% of patents were filed and 4% of patents were granted in Q2 2024.
For comprehensive analysis of UCB's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.